Antihyperlipidemic and hepatoprotective effects of Gardenin A in cellular and high fat diet fed rodent models

Chemico-Biological Interactions

Volumn 269, Issue , 2017, Pages 9-17

  Toppo, Erenius ^a   Darvin, S Sylvester ^a   Esakkimuthu, S ^a   Stalin, A ^a   Balakrishna, K ^a   Sivasankaran, K ^a   Pandikumar, P ^a   Ignacimuthu, S ^a,b   Al Dhabi, N A ^c  

^a LOYOLA COLLEGE   (India)

^b KING SAUD UNIVERSITY   (Saudi Arabia)

^c KING SAUD UNIVERSITY   (Saudi Arabia)

Author keywords

Adipocyte hypertrophy; Fatty Liver; FXR ; Gardenia lucida; Gardenia resinifera

Indexed keywords

ACID PHOSPHATASE; AMINOTRANSFERASE; FENOFIBRATE; GARDENIN A; LACTATE DEHYDROGENASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OLEIC ACID; PALMITIC ACID; PLANT MEDICINAL PRODUCT; TRIACYLGLYCEROL; TYLOXAPOL; UNCLASSIFIED DRUG; ANTILIPEMIC AGENT; FLAVONE DERIVATIVE; LIPID; MACROGOL DERIVATIVE; PALMITIC ACID DERIVATIVE; PROTECTIVE AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIHYPERLIPIDEMIC AFFECT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL VIABILITY; CHOLESTEROL BLOOD LEVEL; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG SCREENING; DRUG STRUCTURE; GARDENIA; GARDENIA RESINIFERA; HEP-G2 CELL LINE; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VIVO STUDY; IRWIN TEST; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIPOTOXICITY; LIVER PROTECTION; MALE; MTT ASSAY; NONALCOHOLIC FATTY LIVER; NONHUMAN; RAT; RODENT MODEL; STEATOSIS; STRUCTURE ANALYSIS; ANIMAL; BLOOD; CELL SURVIVAL; CHEMICALLY INDUCED; CHEMISTRY; DRUG EFFECTS; HYPERLIPIDEMIAS; LIVER; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; PATHOLOGY; WISTAR RAT;

ANIMALS; CELL SURVIVAL; DIET, HIGH-FAT; FLAVONES; GARDENIA; HEP G2 CELLS; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; LIPIDS; LIVER; MALE; NON-ALCOHOLIC FATTY LIVER DISEASE; OLEIC ACID; PALMITATES; POLYETHYLENE GLYCOLS; PROTECTIVE AGENTS; RATS; RATS, WISTAR;

EID: 85016156021     PISSN: 00092797     EISSN: 18727786     Source Type: Journal    
DOI: 10.1016/j.cbi.2017.03.013     Document Type: Article

References (45)

1. [1] Chalasani, N., Younossi, Z., Lavine, J.E., et al. Diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American College of gastroenterology, and the American gastroenterological association. Hepatology 55 (2012), 2005–2023.
2. [2] Neuschwander-Tetri, B.A., Brunt, E.M., Wehmeier, K.R., et al. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:4 (2003), 1008–1017.
3. [3] Whalley, S., Puvanachandra, P., Desai, A., et al. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs. Clin. Med. 7 (2007), 119–124.
4. [4] Younossi, Z.M., Koenig, A.B., Abdelatif, D., et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64:1 (2016), 73–84.
5. [5] Athyros, V.G., Tziomalos, K., Katsiki, N., et al. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J. Gastroenterol. 21:22 (2015), 6820–6834.
6. [6] Li, S., Meng, F., Liao, X., et al. Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats. PLoS One, 9, 2014, e86724.
7. [7] Ali, R., Cusi, K., New diagnostic and treatment approaches in non-alcoholic fatty liver disease (NAFLD). Ann. Med. 41:4 (2009), 265–278.
8. [8] Xiao, J., Fai-So, K., Liong, E.C., et al. Recent advances in the herbal treatment of non-alcoholic Fatty liver disease. J. Tradit. Complement. Med. 3:2 (2013), 88–94.
9. [9] Anonymous, Wealth of India – Raw Materials. First Supplement Series (Rep. 2013), 2002, CSIR-NISCAIR, New Delhi – 110 012, 3–4.
10. [10] Anonymous, Wealth of India – raw materials. Second Supplement Series, 2007, CSIR-NISCAIR, New Delhi – 110 012, 165–167.
11. [11] Parmer, V.S., Sharma, S.K., Poonam, Novel constituents of Gardenia species – a review. J. Sci. Ind. Res. 59 (2000), 893–903.
12. [12] Tandon, N., (eds.) Phytochemical Reference Standards of Selected Indian Medical Plants, vol. 1, 2010, Indian Council for Medical Research, New Delhi – 110 029, 143–151.
13. [13] Miyake, Y., Suzuki, E., Ohya, S., et al. Lipid-lowering effect of Eriocitrin, the main flavonoid in lemon fruit, in rats on a high-fat and high-cholesterol diet. J. Food Sci. 71 (2006), S633–S637.
14. [14] Morin, B., Nichols, L.A., Zalasky, K.M., et al. The citrus flavonoids hesperetin and nobiletin differentially regulate low density lipoprotein receptor gene transcription in HepG2 liver cells. J. Nutr. 138:7 (2008), 1274–1281.
15. [15] Kumar, S., Pandey, A.K., Chemistry and biological activities of flavonoids: an overview. Sci. World J., 2013, 1–16 Article number 162750.
16. [16] Green, C.O., Wheatley, A.O., McGrowder, D.A., Citrus peel polymethoxylated flavones extract modulates liver and heart function parameters in diet induced hypercholesterolemic rats. Food Chem. Toxicol. 51 (2013), 306–309.
17. [17] Manach, C., Regerat, F., Texier, O., et al. Bioavailability, metabolism and physiological impact of 4-oxo-flavonoids. Nutr. Res. 16:3 (1996), 517–544.
18. [18] Koirala, N., Enhancing the pharmaceutical properties of flavonoids via methylation and glycosylation. SOJ Biochem., 2(2), 2016, 2.
19. [19] Sy-Cordero, A.A., Graf, T.N., Runyon, S.P., et al. Enhanced bioactivity of silybin B methylation products. Bioorg. Med. Chem. 21:3 (2013), 742–747.
20. [20] Mosmann, T., Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Immunol. Methods 65 (1983), 55–63.
21. [21] Jang, E., Shin, M.H., Kim, S.K., et al. Anti-lipoapoptotic effect of Artemisia capillaris extract on free fatty acids-induced HepG2 cells. Complement. Alt. Med., 14, 2014, 253.
22. [22] Ramirez-Zacarias, J.L., Castro-Mufiozledo, F., Kuri-Harcuch, W., Quantitation of adipose conversion and triglycerides by staining intracytoplasmic lipids with oil red O. Histochemistry 97:6 (1992), 493–497.
23. [23] Yao, J., Zhi, M., Chen, M., et al. Effect of silybin on high-fat-induced fatty liver in rats. Braz J. Med. Biol. Res. 44 (2011), 652–659.
24. [24] Roux, S., Sable, E., Porsolt, R.D., Primary observation (Irwin) test in rodents for assessing acute toxicity of a test agent and its effect on behavior and physiological function. Curr. Protoc. Pharmacol. 10 (2004), 1–23.
25. [25] Vogel, H.G., Vogel, W.H., Anti-atherosclerotic activity: triton-induced hyperlipidaemia. Heidelberg. (Chapter L) Drug Discovery and Evaluation – Pharmacological Assays. Springer-Vergal, 1997, 606.
26. [26] Levine, S., Saltzman, A., A procedure for inducing sustained hyperlipidemia in rats by administration of a surfactant. J. Pharmacol. Toxicol. Methods 55 (2007), 224–226.
27. [27] Novelli, E.L.B., Diniz, Y.S., Galhardi, C.M., et al. Anthropometrical parameters and markers of obesity in rats. Lab. Anim. 41 (2007), 111–119.
28. [28] Friedewald, W.T., Levy, R.I., Fredrickson, D.S., Estimation of the concentration of Low-Density Lipoprotein Cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18 (1972), 499–502.
29. [29] Parmar, V.S., Hisht, K.S., Sharma, S.K., et al. Highly oxygenated bioactive flavones from taxmarin. Phytochemistry 36:2 (1994), 507–511.
30. [30] Armstrong, M.J., Adams, L.A., Canbay, A., et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59:3 (2014), 1174–1197.
31. [31] Kim, D., Choi, S.-Y., Park, E.H., et al. Nonalcoholic fatty liver disease is associated with coronary artery calcification. Hepatol. Baltim. Md, 56(2), 2012, 10.
32. [32] Orlic, L., Mikolasevic, I., Bagic, Z., et al. Chronic kidney disease and nonalcoholic fatty liver disease-is there a link?. Gastroenterol. Res. Pract., 6, 2014, 847539.
33. [33] Michelotti, G.A., Machado, V., Diehl, A.M., NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 656–665.
34. [34] Dyson, J.K., Anstee, Q.M., McPherson, S., Non-alcoholic fatty liver disease: a practical approach to treatment. Frontline Gastroenterol. 5 (2014), 277–286.
35. [35] Cui, W., Chen, S.L., Hu, K.Q., Quantification and mechanisms of oleic acid-induced steatosis in HepG2 cells. Am. J. Transl. Res. 2:1 (2010), 95–104.
36. [36] Shi, D., Zhan, X., Yu, X., et al. Inhibiting CB1 receptors improves lipogenesis in an in vitro non-alcoholic fatty liver disease model. Lipids Health Dis., 13, 2014, 173.
37. [37] Yao, H.R., Liu, J., Plumeri, D., et al. Lipotoxicity in HepG2 cells triggered by free fatty acids. Am. J. Transl. Res. 3:3 (2011), 284–291.
38. [38] Lutz, T.A., Woods, S.C., Overview of animal models of obesity. Curr. Protoc. Pharmacol., 5, 2012, 61.
39. [39] Nakamura, A., Terauchi, Y., Lessons from mouse models of high-fat diet-induced NAFLD. Int. J. Mol. Sci. 14:11 (2013), 21240–21257.
40. [40] Leite, N.C., Salles, G.F., Araujo, A.L., et al. Prevalence and associated factors of non-alcoholic fatty liver disease in patients with type-2 diabetes mellitus. Liver Int. 29:1 (2009), 113–119.
41. [41] Rodriguez, G., Gallego, S., Breidenassel, C., et al. Is liver transaminases assessment an appropriate tool for the screening of non-alcoholic fatty liver disease in at risk obese children and adolescents?. Nutr. Hosp. 25:5 (2010), 712–717.
42. [42] Sattar, N., Forrest, E., Preiss, D., Non-alcoholic fatty liver disease. Br. Med. J., 349, 2014, g4596.
43. [43] Kim, J.I., Huh, J.Y., Sohn, J.H., et al. Lipid-overloaded enlarged adipocytes provoke insulin resistance independent of inflammation. Mol. Cell Biol. 35:10 (2015), 1686–1699.
44. [44] Henninger, A.M., Eliasson, B., Jenndahl, L.E., et al. Adipocyte hypertrophy, inflammation and fibrosis characterize subcutaneous adipose tissue of healthy, non-obese subjects predisposed to type 2 diabetes. PLoS One, 9(8), 2014, e105262.
45. [45] Cipriani, S., Mencarelli, A., Palladino, G., et al. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J. Lipid Res. 51 (2010), 771–784.